Authors
Latest:
Beyond the Buzzword: Finding Your Patient CentricitySponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:
Latest:
FDA's Helping Hand to Small PharmaFDA's Brenda Stodart outlines the services of the Agency's Small Business and Industry Assistance (SBIA) Program.
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
Expedite Regulated Documents in the Era of COVID-19: From Development to Trials and ManufacturingTechnology is more critical than ever to help you keep your clinical trials on track during the era of COVID-19. Gain best practices about how to empower your remote workforce, get critical regulated documents electronically signed compliantly, and to create a safe and flexible remote patient-centric experience. Live: Wednesday, Jul. 15, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Jul. 15, 2021. Register free
Latest:
UK Biopharma: Life After BrexitPaul Ranson examines how the UK biopharma must now adapt to a changing landscape.
Latest:
Life Sciences' Shifting Sands: 5 Trends that Threaten the Status QuoIf pharma companies want to hold their own in the current climate, they must embrace rather than resist market change.
Latest:
Cuozzo v Lee: How Many Bites at the Apple are Enough?Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
Latest:
The ‘Cure’-All for 21st Century Data SharingBalancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.
Latest:
What Key Opinion Leaders Really Want from PharmaIncreased scrutiny and new regulation have seen pharma’s relationship with key opinion leaders (KOLs) undergo a paradigm shift in recent years.
Latest:
New Challenge to IP InnovationSurvey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Latest:
Building a Digital Health InfrastructureOutlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.
Latest:
Brexit Report: What's Next for the Industry?As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Latest:
‘Huge Sellers’ Herald Changes in Japan Drug PricingThe latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?
Latest:
Eight Characteristics of Blockbuster TeamsThe secret sauce for creating blockbuster brands has always been - and always will be - consistently exceptional team execution. Andy Mehrotra offers the recipe.
Latest:
Emerging Pharma Leaders: Kaya Pai PanandikerVice President, Psychiatry Marketing, Lundbeck US
Latest:
New Challenge to IP InnovationSurvey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Latest:
Content Marketing’s Data Fail: Information Without Insight?A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.
Latest:
The Evolution of Regulatory OperationsMichael Gordon charts the evolution of regulatory operations and suggests how it can spearhead opportunities for innovation in pharma data.
Latest:
To Reduce Commercial Risk for Orphan Drugs, Transform ForecastingTo successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Latest:
As Change Continues, Are You Digitally Fit For the Future?Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.
Latest:
Human Rights on the Pharma Risk Management AgendaMilana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
